TY - JOUR
T1 - Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer
T2 - External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts
AU - The Movember Foundations Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium
AU - Drost, Frank Jan H.
AU - Nieboer, Daan
AU - Morgan, Todd M.
AU - Carroll, Peter R.
AU - Roobol, Monique J.
AU - Trock, Bruce
AU - Ehdaie, Behfar
AU - Carroll, Peter
AU - Filson, Christopher
AU - Kim, Jeri
AU - Logothetis, Christopher
AU - Morgan, Todd
AU - Klotz, Laurence
AU - Pickles, Tom
AU - Hyndman, Eric
AU - Moore, Caroline M.
AU - Gnanapragasam, Vincent
AU - Van Hemelrijck, Mieke
AU - Dasgupta, Prokar
AU - Bangma, Chris
AU - Roobol, Monique
AU - Villers, Arnauld
AU - Rannikko, Antti
AU - Valdagni, Riccardo
AU - Perry, Antoinette
AU - Hugosson, Jonas
AU - Rubio-Briones, Jose
AU - Bjartell, Anders
AU - Hefermehl, Lukas
AU - Shiong, Lee Lui
AU - Frydenberg, Mark
AU - Kakehi, Yoshiyuki
AU - Chung, Byung Ha
AU - van der Kwast, Theo
AU - van der Linden, Wim
AU - Hulsen, Tim
AU - de Jonge, Cees
AU - Kattan, Mike
AU - Xinge, Ji
AU - Muir, Kenneth
AU - Lophatananon, Artitaya
AU - Fahey, Michael
AU - Steyerberg, Ewout
AU - Zhang, Liying
AU - Beckmann, Kerri
AU - Denton, Brian
AU - Hayen, Andrew
AU - Boutros, Paul
AU - Guo, Wei
AU - Benfante, Nicole
N1 - Funding Information:
Funding/Support and role of the sponsor : This work was supported by the Movember Foundation. The funder did not play any role in the study design, collection, analysis, or interpretation of data, or in the drafting of this paper.
Funding Information:
Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium are listed in the Supplementary material.
Publisher Copyright:
© 2019 European Association of Urology
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings.
AB - Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings.
UR - http://www.scopus.com/inward/record.url?scp=85070880610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070880610&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2019.07.041
DO - 10.1016/j.eururo.2019.07.041
M3 - Article
C2 - 31451332
AN - SCOPUS:85070880610
SN - 0302-2838
VL - 76
SP - 693
EP - 702
JO - European Urology
JF - European Urology
IS - 5
ER -
